Literature DB >> 31483438

Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults.

Peder L Myhre1,2, Brian Claggett1, Christie M Ballantyne3, Elizabeth Selvin4, Helge Røsjø2, Torbjørn Omland2, Scott D Solomon1, Hicham Skali1, Amil M Shah1.   

Abstract

Importance: Cardiac troponin is associated with incident heart failure and greater left ventricular (LV) mass. Its association with LV systolic and diastolic functions is unclear.
Objectives: To define the association of high-sensitivity cardiac troponin T (hs-cTnT) with LV systolic and diastolic functions in the general population, and to evaluate the extent to which that association accounts for the correlation between hs-cTnT concentration and incident heart failure overall, heart failure with preserved LV ejection fraction (LVEF; HFpEF), and heart failure with LVEF less than 50%. Design, Setting, and Participants: This analysis of the Atherosclerosis Risk in Communities (ARIC) Study, an ongoing epidemiologic cohort study in US communities, included participants without cardiovascular disease (n = 4111). Available hs-cTnT measurements for participants who attended ARIC Study visits 2 (1990 to 1992), 4 (1996 to 1998), and 5 (2011 to 2013) were assessed cross-sectionally against echocardiographic measurements taken at visit 5 and against incident health failure after visit 5. Changes in hs-cTnT concentrations from visits 2 and 4 were also examined. Data analyses were performed from August 2017 to July 2018. Main Outcomes and Measures: Cardiac structure and function by echocardiography at visit 5, and incident heart failure during a median 4½ years follow-up after visit 5.
Results: Of the 6538 eligible participants, 4111 (62.9%) without cardiovascular disease were included. Among these participants, 2586 (62.9%) were female, and the mean (SD) age was 75 (5) years. Median (interquartile range) hs-cTnT concentration at visit 5 was 9 (7-14) ng/L and was detectable in 3946 participants (96.0%). After adjustment for demographic and clinical covariates, higher hs-cTnT levels were associated with greater LV mass index (adjusted mean [SE] for group 1: 33.8 [0.5] vs group 5: 40.1 [0.4]; P for trend < .001) and with worse diastolic function, including lower tissue Doppler imaging e' (6.00 [0.07] vs 5.54 [0.06]; P for trend < .001), higher E/e' ratio (11.4 [0.2] vs 12.9 [0.1]; P for trend < .001), and greater left atrial volume index (23.4 [0.4] vs 26.4 [0.3]; P for trend < .001), independent of LV mass index; hs-cTnT level was not associated with measures of LV systolic function. Accounting for diastolic function attenuated the association of hs-cTnT concentration with incident HFpEF by 41% and the association with combined heart failure with midrange and reduced ejection fraction combined (LVEF <50) by 17%. Elevated hs-cTnT concentration and diastolic dysfunction were additive risk factors for incident heart failure. For any value of late-life hs-cTnT levels, longer duration of detectable hs-cTnT from midlife to late life was associated with greater LV mass in late life but not with worse LV systolic or diastolic function. Conclusions and Relevance: This study shows that higher hs-cTnT concentrations were associated with worse diastolic function, irrespective of LV mass, but not with systolic function; these findings suggest that high levels of hs-cTnT may serve as an early marker of subclinical alterations in diastolic function that may lead to a predisposition to heart failure.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31483438      PMCID: PMC6727783          DOI: 10.1001/jamacardio.2019.3113

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  15 in total

1.  Are Cardiac Biomarkers to Predict Cardiovascular Outcomes in Patients with Chronic Kidney Disease Ready for Prime Time?

Authors:  Jenny I Shen; Keith C Norris
Journal:  Mayo Clin Proc       Date:  2019-11       Impact factor: 7.616

2.  Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts.

Authors:  Kershaw V Patel; Matthew W Segar; Carl J Lavie; Nitin Kondamudi; Ian J Neeland; Jaime P Almandoz; Corby K Martin; Salvatore Carbone; Javed Butler; Tiffany M Powell-Wiley; Ambarish Pandey
Journal:  Circulation       Date:  2021-12-03       Impact factor: 29.690

3.  Ultra-high sensitivity cardiac troponin-I concentration and left ventricular structure and function in women with ischemia and no obstructive coronary artery disease.

Authors:  Odayme Quesada; Omeed Elboudwarej; Michael D Nelson; Ahmed Al-Badri; Mitra Mastali; Janet Wei; Bijan Zarrabi; Nissi Suppogu; Haider Aldiwani; Puja Mehta; Chrisandra Shufelt; Galen Cook-Wiens; Daniel S Berman; Louise E J Thomson; Eileen Handberg; Carl J Pepine; Jennifer E Van Eyk; C Noel Bairey Merz
Journal:  Am Heart J Plus       Date:  2022-03-03

4.  Cardiac biomarkers in pediatric CKD-a prospective follow-up study.

Authors:  Ylva Tranæus Lindblad; Georgios Vavilis; Milan Chromek; Abdul Rashid Quershi; Christian Löwbeer; Peter Bárány
Journal:  Pediatr Nephrol       Date:  2022-03-16       Impact factor: 3.651

Review 5.  Myocardial injury, troponin release, and cardiomyocyte death in brief ischemia, failure, and ventricular remodeling.

Authors:  John M Canty
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-05-13       Impact factor: 5.125

6.  Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study).

Authors:  Aliza Hussain; Olive Tang; Caroline Sun; Xiaoming Jia; Elizabeth Selvin; Vijay Nambi; Aaron Folsom; Gerardo Heiss; Faiez Zannad; Thomas Mosley; Salim S Virani; Josef Coresh; Eric Boerwinkle; Bing Yu; Jonathan W Cunningham; Amil M Shah; Scott D Solomon; James A de Lemos; Ron C Hoogeveen; Christie M Ballantyne
Journal:  Am J Cardiol       Date:  2021-02-02       Impact factor: 2.778

7.  Biomarker profiling for risk of future heart failure (HFpEF) development.

Authors:  Chris J Watson; Joe Gallagher; Mark Wilkinson; Adam Russell-Hallinan; Isaac Tea; Stephanie James; James O'Reilly; Eoin O'Connell; Shuaiwei Zhou; Mark Ledwidge; Ken McDonald
Journal:  J Transl Med       Date:  2021-02-09       Impact factor: 5.531

8.  Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease.

Authors:  Jiatian Cao; Yan Zheng; Zhe Luo; Zhendong Mei; Yumeng Yao; Zilong Liu; Chao Liang; Hongbo Yang; Yanan Song; Kaihuan Yu; Yan Gao; Chouwen Zhu; Zheyong Huang; Juying Qian; Junbo Ge
Journal:  Theranostics       Date:  2020-07-29       Impact factor: 11.556

9.  Potential determinants of the E/e' ratio in non-dialysis compared with dialysis patients.

Authors:  Hon-Chun Hsu; Gavin R Norton; Chanel Robinson; Angela J Woodiwiss; Patrick H Dessein
Journal:  Nephrology (Carlton)       Date:  2021-07-27       Impact factor: 2.358

10.  APOL1 Risk Alleles, Cardiac Markers, and Risk of ESKD in African Americans: The Atherosclerosis Risk in Communities Study.

Authors:  Aditya L Surapaneni; Shoshana H Ballew; Josef Coresh; Christie M Ballantyne; Elizabeth Selvin; Kunihiro Matsushita; Morgan E Grams
Journal:  Kidney Med       Date:  2020-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.